Vivoryon Therapeutics N.V. Financial Statements
Condensed Statements of Profit or Loss and Other Comprehensive Income for the six months ended June 30, 2022 and 2021
For the six months
ended June 30,
in kEUR, except for share data 2022 2021
Research and development expenses (11,067) (9,456)
General and administrative expenses (2,311) (2,337)
Other operating income — 5
Operating loss (13,378) (11,788)
Finance income 989 219
Finance expenses (105) (102)
Finance result 884 117
Result before income taxes (12,494) (11,671)
Income taxes (89) —
Net loss for the period (12,583) (11,671)
Items not to be reclassified subsequently to profit or loss
Remeasurement of the net defined benefit pension liability 261 —
Total other comprehensive income / (loss) 261 —
Comprehensive loss (12,322) (11,671)
Loss per share in EUR (basic and diluted) (0.60) (0.58)
The accompanying notes are an integral part of these condensed interim financial statements.
Vivoryon Therapeutics N.V.
Condensed Statements of Financial Position
in kEUR June 30,
2022 December 31,
2021
ASSETS
Non-current assets
Intangible assets 512 533
Property, plant and equipment 54 66
Right-of-use assets 173 219
Financial assets 14 3,473
Total non-current assets 753 4,291
Current assets
Financial assets 3,812 3,074
Other current assets and prepayments 2,795 2,494
Cash and cash equivalents 24,383 14,661
Total current assets 30,990 20,229
TOTAL ASSETS 31,743 24,520
Equity
Share capital 22,050 20,050
Share premium 101,181 83,211
Other capital reserves 7,200 6,168
Accumulated other comprehensive loss (311) (572)
Accumulated deficit (104,883) (92,300)
Total equity 25,237 16,557
Non-current liabilities
Pension liability 1,505 1,823
Provisions long-term 12 12
Lease liabilities 86 132
Other liabilities — 513
Deferred tax liabilities 521 432
Total non-current liabilities 2,124 2,912
Current liabilities
Provisions 35 35
Trade payables 3,681 4,360
Lease liabilities 93 92
Other liabilities 573 564
Total current liabilities 4,382 5,051
Total Liabilities 6,506 7,963
TOTAL EQUITY AND LIABILITIES 31,743 24,520
The accompanying notes are an integral part of these condensed interim financial statements.
Vivoryon Therapeutics N.V.
Statements of Changes in Shareholders’ Equity for the six months ended June 30, 2022 and 2021
(in kEUR) Sha